Share this Post!

Under FDA Circular 2021-008 or the Updated Guidelines for the Registration of Drug Products Under Emergency Use (DEU) for COVID-19, licensed drug establishments intending to manufacture and import/ distribute drug products listed in the Philippine COVID-19 Living Recommendations may register as DEU provided that such drug products have a positive recommendation and a registered counterpart with the FDA at the time of the application.

 

As of 2 September 2021, the following products may be registered as Drug Products under Emergency Use (DEU) for COVID-19:  

 

Generic Name Strength Dosage Form
Tocilizumab 400 mg/ 20 mL Concentrate Solution for Infusion (IV)
80 mg/ 4 mL (20 mg/mL) Concentrate Solution for Infusion  (IV)
200 mg/ 10 mL Concentrate Solution for Infusion (IV)
Baricitinib 2 mg Tablet
4 mg Tablet
Dexamethasone (as sodium phosphate) 4 mg/mL Solution for Injection (IM/IV)
50 mg/mL Solution for Injection (IM/IV)
4 mg/mL (8 mg/ 2 mL) Solution for Injection (IM/IV)
5 mg/ mL Solution for Injection (IM/IV)
2 mg/mL Solution for Injection (IM/IV)
Heparin Sodium 5,000 IU/ mL (25,000 IU/ 5mL) Solution for Injection (IV/SC)
1,000 IU/ mL (5,000 IU/ 5mL) Solution for Injection (IV/SC)
1000 IU/ mL Solution for Injection (IV/SC)
5000 IU/mL Solution for Injection (IV/SC)

 

Enoxaparin Sodium 60mg/0.6mL Solution For Injection (SC)
40 mg/0.4 mL Solution for Injection (SC)
4,000 IU Anti-Factor Xa (equivalent to 40mg) / 0.4mL Solution for Injection (IV/SC)
2,000 IU Anti-Factor Xa (equivalent to 20mg) / 0.2mL Solution for Injection (IV/SC)
6,000 IU Anti-Factor Xa (equivalent to 60mg) / 0.6mL Solution for Injection (IV/SC)
20mg/ 0.2mL Solution for Injection (IV/SC)
Bivalirudin 250 mg Lyophilized Powder for Injection (I.V.)
Tinzaparin sodium 10000 anti-Xa IU/mL Solution For Injection (SC)
Dalteparin Sodium 2500 I.U/0.2 mL Solution Solution For Injection In Pre-Filled Syringe

 

For the information and guidance of all.

 

Attachments